Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models | Zendy

Kader Yagiz | Zendy; Tiffany Huang | Zendy; Fernando Lopez Espinoza | Zendy; Daniel Mendoza | Zendy; Carlos E. Ibañez | Zendy; Harry E. Gruber | Zendy; Douglas J. Jolly | Zendy; Joan M. Robbins | Zendy

Open Access

Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models

Author(s) -

Kader Yagiz,

Tiffany Huang,

Fernando Lopez Espinoza,

Daniel Mendoza,

Carlos E. Ibañez,

Harry E. Gruber,

Douglas J. Jolly,

Joan M. Robbins

Publication year - 2016

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/now089

Subject(s) - lomustine , glioma , medicine , cancer research , immunology , chemotherapy , vincristine , cyclophosphamide

Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, used in combination with 5-fluorocytosine (5-FC) kills tumor by local production of 5-fluorouracil (5-FU), inducing local and systemic immunotherapeutic response resulting in long-term survival after cessation of 5-FC. Toca 511 and Toca FC (oral extended-release 5-FC) are under investigation in patients with recurrent high-grade glioma. Lomustine is a treatment option for patients with high-grade glioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog